WALTHAM, Mass., Aug. 17, 2022 (GLOBE NEWSWIRE) — AVAVA Inc. (“AVAVA” or the “Company”), a disruptive medical aesthetics technology platform company providing breakthrough treatments for all skin tones, today announced that its AVAVA pigment disorder product has received FDA 510(k) clearance to treat benign pigmented lesions of the skin, including hyperpigmentation.
Read the full announcement featuring our own Dr. Geronemus at PR Newswire.
| Title | Address | Description |
|---|---|---|
Manhattan | 317 E 34th St, New York, NY 10016, USA |
|
Southampton | 325 Meeting House Ln Building 1, Suite C, Southampton, NY 11968, USA |
|
| Title | Address | Description |
|---|---|---|
Manhattan | 317 E 34th St, New York, NY 10016, USA |
|
Southampton | 325 Meeting House Ln Building 1, Suite C, Southampton, NY 11968, USA |
|
By LASER & SKIN SURGERY CENTER OF NEW YORK® | © 2026 All Rights Reserved. | Privacy Policy |The information available on this web site is provided for informational purposes only. This information is not intended to replace a medical consultation where a physician's judgment may advise you about specific disorders, conditions and or treatment options. We hope the information will be useful for you to become more educated about your health care decisions. If you are vision-impaired or have some other impairment covered by the Americans with Disabilities Act or a similar law, and you wish to discuss potential accommodations related to using this website, please contact us at 212.941.5055.
*MDs perform 100% of all medical and cosmetic treatments.
